{"transactions":[{"id":4613466,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":51792,"kind":"person","name":"Chin Peter Scott","position":1,"cik":"0002124755","reported_name":"Chin Peter Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-09T20:44:33.000Z","date":"2026-09-04","kind":"sale","planned":false,"acquired":false,"shares":1654,"price":22.29,"value":36867.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.28 to $22.29 per share. Upon request by the Commission staff, the Issuer, or a\nsecurity holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 142,845 Unvested RSU's"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 1,790 shares acquired under the ESPP Purchase on June 1, 2026."}],"balance_after":204538,"source":{"system":"sec-edgar","filing":"0002124755-26-000007","document":"wk-form4_1788986671.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2124755/000212475526000007/wk-form4_1788986671.xml","form_type":"4"}},{"id":4730,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":10183,"kind":"person","name":"Thornberry Nancy","position":1,"cik":"0001797826","reported_name":"Thornberry Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-04T21:02:24.000Z","date":"2026-09-02","kind":"sale","planned":true,"acquired":false,"shares":615,"price":23.74,"value":14600.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted June 3, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.59 to $23.85 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 6,408 Unvested RSUs."}],"balance_after":19686,"source":{"system":"sec-edgar","filing":"0001797826-26-000006","document":"wk-form4_1788555742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1797826/000179782626000006/wk-form4_1788555742.xml","form_type":"4"}},{"id":4729,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":10183,"kind":"person","name":"Thornberry Nancy","position":1,"cik":"0001797826","reported_name":"Thornberry Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-04T21:02:24.000Z","date":"2026-09-02","kind":"sale","planned":true,"acquired":false,"shares":10824,"price":22.85,"value":247328.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted June 3, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.54 to $23.52 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 6,408 Unvested RSUs."}],"balance_after":20301,"source":{"system":"sec-edgar","filing":"0001797826-26-000006","document":"wk-form4_1788555742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1797826/000179782626000006/wk-form4_1788555742.xml","form_type":"4"}},{"id":2268,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":1736,"kind":"person","name":"Schuth Alexander O.","position":1,"cik":"0001724311","reported_name":"Schuth Alexander O.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COFO and Secretary"}}],"security":"Common Stock","published_at":"2026-09-03T20:17:38.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":2768,"price":23.44,"value":64881.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 135,475 Unvested RSUs."}],"balance_after":278995,"source":{"system":"sec-edgar","filing":"0001724311-26-000014","document":"wk-form4_1788466654.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724311/000172431126000014/wk-form4_1788466654.xml","form_type":"4"}},{"id":686963,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":23347,"kind":"person","name":"Watts Ryan J.","position":1,"cik":"0001724310","reported_name":"Watts Ryan J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-14T20:48:18.000Z","date":"2026-08-12","kind":"gift","planned":false,"acquired":false,"shares":32220,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an in-kind charitable contribution of 32,220 shares of DNLI to a donor advised fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee."}],"balance_after":2120384,"source":{"system":"sec-edgar","filing":"0001724310-26-000007","document":"wk-form4_1786740495.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724310/000172431026000007/wk-form4_1786740495.xml","form_type":"4"}},{"id":688020,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":1736,"kind":"person","name":"Schuth Alexander O.","position":1,"cik":"0001724311","reported_name":"Schuth Alexander O.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COFO and Secretary"}}],"security":"Common Stock","published_at":"2026-08-13T21:01:59.000Z","date":"2026-08-11","kind":"sale","planned":false,"acquired":false,"shares":2857,"price":25.07,"value":71624.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 135,475 Unvested RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,792 shares acquired under the ESPP Purchase on June 1, 2026."}],"balance_after":281763,"source":{"system":"sec-edgar","filing":"0001724311-26-000013","document":"wk-form4_1786654917.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724311/000172431126000013/wk-form4_1786654917.xml","form_type":"4"}},{"id":748027,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":35935,"kind":"person","name":"FLATLEY JAY T","position":1,"cik":"0001189130","reported_name":"FLATLEY JAY T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-05T20:46:26.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":19226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":19226,"derivative":{"exercise_price":19.66,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":19226},"source":{"system":"sec-edgar","filing":"0001189130-26-000005","document":"wk-form4_1780692384.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000118913026000005/wk-form4_1780692384.xml","form_type":"4"}},{"id":748026,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":35935,"kind":"person","name":"FLATLEY JAY T","position":1,"cik":"0001189130","reported_name":"FLATLEY JAY T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:46:26.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":6408,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,408 unvested RSUs."}],"balance_after":22628,"source":{"system":"sec-edgar","filing":"0001189130-26-000005","document":"wk-form4_1780692384.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000118913026000005/wk-form4_1780692384.xml","form_type":"4"}},{"id":748025,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":12811,"kind":"person","name":"Klein Peter S","position":1,"cik":"0001478007","reported_name":"Klein Peter S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-05T20:45:59.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":19226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":19226,"derivative":{"exercise_price":19.66,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":19226},"source":{"system":"sec-edgar","filing":"0001478007-26-000002","document":"wk-form4_1780692356.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000147800726000002/wk-form4_1780692356.xml","form_type":"4"}},{"id":748024,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":12811,"kind":"person","name":"Klein Peter S","position":1,"cik":"0001478007","reported_name":"Klein Peter S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:45:59.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":6408,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,408 unvested RSUs."}],"balance_after":33941,"source":{"system":"sec-edgar","filing":"0001478007-26-000002","document":"wk-form4_1780692356.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000147800726000002/wk-form4_1780692356.xml","form_type":"4"}},{"id":748023,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":32853,"kind":"person","name":"Krognes Steve E.","position":1,"cik":"0001666236","reported_name":"Krognes Steve E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-05T20:45:43.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":19226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":19226,"derivative":{"exercise_price":19.66,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":19226},"source":{"system":"sec-edgar","filing":"0001666236-26-000015","document":"wk-form4_1780692340.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000166623626000015/wk-form4_1780692340.xml","form_type":"4"}},{"id":748022,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":32853,"kind":"person","name":"Krognes Steve E.","position":1,"cik":"0001666236","reported_name":"Krognes Steve E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:45:43.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":6408,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,408 unvested RSUs."}],"balance_after":38202,"source":{"system":"sec-edgar","filing":"0001666236-26-000015","document":"wk-form4_1780692340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000166623626000015/wk-form4_1780692340.xml","form_type":"4"}},{"id":748017,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-05T20:45:26.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":19226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":19226,"derivative":{"exercise_price":19.66,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":19226},"source":{"system":"sec-edgar","filing":"0001578200-26-000004","document":"wk-form4_1780692324.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000157820026000004/wk-form4_1780692324.xml","form_type":"4"}},{"id":748016,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:45:26.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":6408,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,408 unvested RSUs."}],"balance_after":21665,"source":{"system":"sec-edgar","filing":"0001578200-26-000004","document":"wk-form4_1780692324.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000157820026000004/wk-form4_1780692324.xml","form_type":"4"}},{"id":748021,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":10183,"kind":"person","name":"Thornberry Nancy","position":1,"cik":"0001797826","reported_name":"Thornberry Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-05T20:45:10.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":19226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":19226,"derivative":{"exercise_price":19.66,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":19226},"source":{"system":"sec-edgar","filing":"0001797826-26-000002","document":"wk-form4_1780692307.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000179782626000002/wk-form4_1780692307.xml","form_type":"4"}},{"id":748020,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":10183,"kind":"person","name":"Thornberry Nancy","position":1,"cik":"0001797826","reported_name":"Thornberry Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:45:10.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":6408,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,408 unvested RSUs."}],"balance_after":31125,"source":{"system":"sec-edgar","filing":"0001797826-26-000002","document":"wk-form4_1780692307.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000179782626000002/wk-form4_1780692307.xml","form_type":"4"}},{"id":748144,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":34846,"kind":"person","name":"Van Hauwermeiren Timothy","position":1,"cik":"0001816206","reported_name":"Van Hauwermeiren Timothy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-05T20:44:52.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":19226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":19226,"derivative":{"exercise_price":19.66,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":19226},"source":{"system":"sec-edgar","filing":"0001816206-26-000003","document":"wk-form4_1780692290.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816206/000181620626000003/wk-form4_1780692290.xml","form_type":"4"}},{"id":748143,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":34846,"kind":"person","name":"Van Hauwermeiren Timothy","position":1,"cik":"0001816206","reported_name":"Van Hauwermeiren Timothy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:44:52.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":6408,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 17,040 unvested RSUs."}],"balance_after":17040,"source":{"system":"sec-edgar","filing":"0001816206-26-000003","document":"wk-form4_1780692290.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816206/000181620626000003/wk-form4_1780692290.xml","form_type":"4"}},{"id":748019,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-05T20:43:24.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":19226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":19226,"derivative":{"exercise_price":19.66,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":19226},"source":{"system":"sec-edgar","filing":"0001754371-26-000002","document":"wk-form4_1780692201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000175437126000002/wk-form4_1780692201.xml","form_type":"4"}},{"id":748018,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:43:24.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":6408,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one\nyear anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,408 unvested RSUs."}],"balance_after":32483,"source":{"system":"sec-edgar","filing":"0001754371-26-000002","document":"wk-form4_1780692201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000175437126000002/wk-form4_1780692201.xml","form_type":"4"}},{"id":748621,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non- Qualified Stock Option (right to buy)","published_at":"2026-06-05T20:28:11.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":19226,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F10","text":"19,226 Stock Options exercisable solely into Common Stock were granted under the Incentive Plan to Julian C. Baker in his capacity as a director of the Issuer. The Stock Options have a strike price of $19.66 and expire on June 3, 2036. The Stock Options vest on the earlier of June 3, 2027 or the day prior to the Issuer's Annual Meeting occurring after June 3, 2026, subject to Julian C. Baker's continuous service on the Board through such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"19,226 Stock Options exercisable solely into Common Stock were granted under the Incentive Plan to Julian C. Baker in his capacity as a director of the Issuer. The Stock Options have a strike price of $19.66 and expire on June 3, 2036. The Stock Options vest on the earlier of June 3, 2027 or the day prior to the Issuer's Annual Meeting occurring after June 3, 2026, subject to Julian C. Baker's continuous service on the Board through such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock (\"Stock Options\") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The acquisitions of the RSUs and Stock Options reported on this form represent a single grant to Julian C. Baker of 6,408 RSUs on Table I and 19,226 Stock Options on Table II. These grants, totaling 6,408 RSUs and 19,226 Stock Options for Julian C. Baker, are reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19226,"derivative":{"exercise_price":19.66,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":19226},"source":{"system":"sec-edgar","filing":"0001193125-26-259680","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526259680/ownership.xml","form_type":"4"}},{"id":748620,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-05T20:28:11.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":19226,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F10","text":"19,226 Stock Options exercisable solely into Common Stock were granted under the Incentive Plan to Julian C. Baker in his capacity as a director of the Issuer. The Stock Options have a strike price of $19.66 and expire on June 3, 2036. The Stock Options vest on the earlier of June 3, 2027 or the day prior to the Issuer's Annual Meeting occurring after June 3, 2026, subject to Julian C. Baker's continuous service on the Board through such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"19,226 Stock Options exercisable solely into Common Stock were granted under the Incentive Plan to Julian C. Baker in his capacity as a director of the Issuer. The Stock Options have a strike price of $19.66 and expire on June 3, 2036. The Stock Options vest on the earlier of June 3, 2027 or the day prior to the Issuer's Annual Meeting occurring after June 3, 2026, subject to Julian C. Baker's continuous service on the Board through such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock (\"Stock Options\") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The acquisitions of the RSUs and Stock Options reported on this form represent a single grant to Julian C. Baker of 6,408 RSUs on Table I and 19,226 Stock Options on Table II. These grants, totaling 6,408 RSUs and 19,226 Stock Options for Julian C. Baker, are reported for each of the Funds as each has an indirect pecuniary interest in such securities."}],"balance_after":19226,"derivative":{"exercise_price":19.66,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":19226},"source":{"system":"sec-edgar","filing":"0001193125-26-259680","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526259680/ownership.xml","form_type":"4"}},{"id":748619,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:28:11.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":6408,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 6,408 restricted stock units (each, an \"RSU\") payable solely in common stock (\"Common Stock\") of Denali Therapeutics Inc. (the \"Issuer\") granted by the Issuer to Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") on June 3, 2026, pursuant to the Issuer's 2017 Equity Incentive Plan and Outside Director Compensation Policy (collectively the \"Incentive Plan\"). The RSUs vest on the earlier of June 3, 2027 or the day prior to the Issuer's Annual Meeting occurring after June 3, 2026, subject to Julian C. Baker's continuous service on the board of directors of the Issuer (the \"Board\") through such vesting date. Julian C. Baker serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock (\"Stock Options\") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The acquisitions of the RSUs and Stock Options reported on this form represent a single grant to Julian C. Baker of 6,408 RSUs on Table I and 19,226 Stock Options on Table II. These grants, totaling 6,408 RSUs and 19,226 Stock Options for Julian C. Baker, are reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Includes beneficial ownership of 2,641 shares of Common Stock received previously from vested RSUs and 7,924 shares of Common Stock underlying unvested RSUs that were issued to Julian C. Baker in his capacity as a director of the Issuer, each of which the Funds are deemed to own a portion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":3422366,"source":{"system":"sec-edgar","filing":"0001193125-26-259680","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526259680/ownership.xml","form_type":"4"}},{"id":748618,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:28:11.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":6408,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 6,408 restricted stock units (each, an \"RSU\") payable solely in common stock (\"Common Stock\") of Denali Therapeutics Inc. (the \"Issuer\") granted by the Issuer to Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") on June 3, 2026, pursuant to the Issuer's 2017 Equity Incentive Plan and Outside Director Compensation Policy (collectively the \"Incentive Plan\"). The RSUs vest on the earlier of June 3, 2027 or the day prior to the Issuer's Annual Meeting occurring after June 3, 2026, subject to Julian C. Baker's continuous service on the board of directors of the Issuer (the \"Board\") through such vesting date. Julian C. Baker serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock (\"Stock Options\") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The acquisitions of the RSUs and Stock Options reported on this form represent a single grant to Julian C. Baker of 6,408 RSUs on Table I and 19,226 Stock Options on Table II. These grants, totaling 6,408 RSUs and 19,226 Stock Options for Julian C. Baker, are reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Includes beneficial ownership of 2,641 shares of Common Stock received previously from vested RSUs and 7,924 shares of Common Stock underlying unvested RSUs that were issued to Julian C. Baker in his capacity as a director of the Issuer, each of which the Funds are deemed to own a portion."}],"balance_after":343275,"source":{"system":"sec-edgar","filing":"0001193125-26-259680","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526259680/ownership.xml","form_type":"4"}},{"id":943260,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":23347,"kind":"person","name":"Watts Ryan J.","position":1,"cik":"0001724310","reported_name":"Watts Ryan J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-08T21:20:05.000Z","date":"2026-01-06","kind":"sale","planned":false,"acquired":false,"shares":35198,"price":16.5,"value":580767.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 184,915 Unvested RSUs."}],"balance_after":296833,"source":{"system":"sec-edgar","filing":"0001724310-26-000004","document":"wk-form4_1767907202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724310/000172431026000004/wk-form4_1767907202.xml","form_type":"4"}},{"id":943259,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":1736,"kind":"person","name":"Schuth Alexander O.","position":1,"cik":"0001724311","reported_name":"Schuth Alexander O.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COFO and Secretary"}}],"security":"Common Stock","published_at":"2026-01-08T21:19:45.000Z","date":"2026-01-06","kind":"sale","planned":false,"acquired":false,"shares":17218,"price":16.5,"value":284097.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 141,100 Unvested RSUs."}],"balance_after":282828,"source":{"system":"sec-edgar","filing":"0001724311-26-000005","document":"wk-form4_1767907181.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724311/000172431126000005/wk-form4_1767907181.xml","form_type":"4"}},{"id":951628,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":1736,"kind":"person","name":"Schuth Alexander O.","position":1,"cik":"0001724311","reported_name":"Schuth Alexander O.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COFO and Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-05T23:49:12.000Z","date":"2026-01-03","kind":"grant","planned":false,"acquired":true,"shares":173100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option shall vest on January 3, 2027, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date."}],"balance_after":173100,"derivative":{"exercise_price":16.27,"expiration_date":"2036-01-03","underlying":"Common Stock","underlying_shares":173100},"source":{"system":"sec-edgar","filing":"0001724311-26-000001","document":"wk-form4_1767656950.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1724311/000172431126000001/wk-form4_1767656950.xml","form_type":"4"}},{"id":951627,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":1736,"kind":"person","name":"Schuth Alexander O.","position":1,"cik":"0001724311","reported_name":"Schuth Alexander O.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COFO and Secretary"}}],"security":"Common Stock","published_at":"2026-01-05T23:49:12.000Z","date":"2026-01-03","kind":"grant","planned":false,"acquired":true,"shares":57700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2027 (the \"Vesting\nCommencement Date\") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service\nprovider of the Issuer through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 141,100 Unvested RSUs."}],"balance_after":300046,"source":{"system":"sec-edgar","filing":"0001724311-26-000001","document":"wk-form4_1767656950.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724311/000172431126000001/wk-form4_1767656950.xml","form_type":"4"}},{"id":951630,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":23347,"kind":"person","name":"Watts Ryan J.","position":1,"cik":"0001724310","reported_name":"Watts Ryan J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-05T23:48:48.000Z","date":"2026-01-03","kind":"grant","planned":false,"acquired":true,"shares":236880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option shall vest on January 3, 2027, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date"}],"balance_after":236880,"derivative":{"exercise_price":16.27,"expiration_date":"2036-01-03","underlying":"Common Stock","underlying_shares":236880},"source":{"system":"sec-edgar","filing":"0001724310-26-000001","document":"wk-form4_1767656925.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1724310/000172431026000001/wk-form4_1767656925.xml","form_type":"4"}},{"id":951629,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":23347,"kind":"person","name":"Watts Ryan J.","position":1,"cik":"0001724310","reported_name":"Watts Ryan J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-05T23:48:48.000Z","date":"2026-01-03","kind":"grant","planned":false,"acquired":true,"shares":78960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2027 (the \"Vesting\nCommencement Date\") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service\nprovider of the Issuer through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 184,915 Unvested RSUs."}],"balance_after":332031,"source":{"system":"sec-edgar","filing":"0001724310-26-000001","document":"wk-form4_1767656925.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724310/000172431026000001/wk-form4_1767656925.xml","form_type":"4"}},{"id":970012,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"$0.01 Prefunded Warrants","published_at":"2025-12-15T21:33:24.000Z","date":"2025-12-11","kind":"purchase","planned":false,"acquired":true,"shares":2095191,"price":17.49,"value":36644890.59,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") purchased, respectively, 190,523 and 2,095,191 warrants to purchase common stock (\"Common Stock\") of Denali Therapeutics Inc. (the \"Issuer\") at an exercise price of $0.01 per share with no expiration date (\"$0.01 Prefunded Warrants\") for $17.49 per share in a public offering that closed on December 11, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The $0.01 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more thn 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\"). By written notice to the Issuer, the Funds may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The $0.01 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more thn 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\"). By written notice to the Issuer, the Funds may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") purchased, respectively, 190,523 and 2,095,191 warrants to purchase common stock (\"Common Stock\") of Denali Therapeutics Inc. (the \"Issuer\") at an exercise price of $0.01 per share with no expiration date (\"$0.01 Prefunded Warrants\") for $17.49 per share in a public offering that closed on December 11, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":25996310,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":2095191},"source":{"system":"sec-edgar","filing":"0001193125-25-319291","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525319291/ownership.xml","form_type":"4"}},{"id":970011,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"$0.01 Prefunded Warrants","published_at":"2025-12-15T21:33:24.000Z","date":"2025-12-11","kind":"purchase","planned":false,"acquired":true,"shares":190523,"price":17.49,"value":3332247.27,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") purchased, respectively, 190,523 and 2,095,191 warrants to purchase common stock (\"Common Stock\") of Denali Therapeutics Inc. (the \"Issuer\") at an exercise price of $0.01 per share with no expiration date (\"$0.01 Prefunded Warrants\") for $17.49 per share in a public offering that closed on December 11, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The $0.01 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more thn 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\"). By written notice to the Issuer, the Funds may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The $0.01 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more thn 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\"). By written notice to the Issuer, the Funds may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") purchased, respectively, 190,523 and 2,095,191 warrants to purchase common stock (\"Common Stock\") of Denali Therapeutics Inc. (the \"Issuer\") at an exercise price of $0.01 per share with no expiration date (\"$0.01 Prefunded Warrants\") for $17.49 per share in a public offering that closed on December 11, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":2335469,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":190523},"source":{"system":"sec-edgar","filing":"0001193125-25-319291","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525319291/ownership.xml","form_type":"4"}},{"id":1005869,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":34846,"kind":"person","name":"Van Hauwermeiren Timothy","position":1,"cik":"0001816206","reported_name":"Van Hauwermeiren Timothy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-07T01:16:39.000Z","date":"2025-11-04","kind":"grant","planned":false,"acquired":true,"shares":31897,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option shall vest on November 4, 2026, and an additional 1/48 of the shares subject to the option vest each month thereafter, subject to the Reporting Person remaining a non-employee director of the Issuer through each such date"}],"balance_after":31897,"derivative":{"exercise_price":14.92,"expiration_date":"2034-11-04","underlying":"Common Stock","underlying_shares":31897},"source":{"system":"sec-edgar","filing":"0001816206-25-000007","document":"wk-form4_1762478196.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816206/000181620625000007/wk-form4_1762478196.xml","form_type":"4"}},{"id":1005868,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":34846,"kind":"person","name":"Van Hauwermeiren Timothy","position":1,"cik":"0001816206","reported_name":"Van Hauwermeiren Timothy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T01:16:39.000Z","date":"2025-11-04","kind":"grant","planned":false,"acquired":true,"shares":10632,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer.  The RSU award vests over a four-year period, with 1/4th of the shares vesting on each anniversary of the grant date (or, for the last tranche that otherwise would vest on the fourth anniversary of the grant date, on such anniversary or, if earlier, on the day prior to the Company's next annual meeting of stockholders occurring after the third anniversary of the grant date), provided that he remains a non-employee director through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 10,632 unvested RSUs."}],"balance_after":10632,"source":{"system":"sec-edgar","filing":"0001816206-25-000007","document":"wk-form4_1762478196.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816206/000181620625000007/wk-form4_1762478196.xml","form_type":"4"}},{"id":1046831,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":23347,"kind":"person","name":"Watts Ryan J.","position":1,"cik":"0001724310","reported_name":"Watts Ryan J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-05T20:43:51.000Z","date":"2025-09-03","kind":"gift","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an in-kind charitable contribution of 50,000 shares of DNLI to a donor advised fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee."}],"balance_after":2152604,"source":{"system":"sec-edgar","filing":"0001724310-25-000005","document":"wk-form4_1757105029.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724310/000172431025000005/wk-form4_1757105029.xml","form_type":"4"}},{"id":1066484,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":1736,"kind":"person","name":"Schuth Alexander O.","position":1,"cik":"0001724311","reported_name":"Schuth Alexander O.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COFO and Secretary"}}],"security":"Common Stock","published_at":"2025-08-15T00:33:49.000Z","date":"2025-08-12","kind":"sale","planned":false,"acquired":false,"shares":2937,"price":13.58,"value":39884.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $13.35 to $13.58 per share. Upon request by the Commission staff, the Issuer, or a\nsecurity holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 128,405 Unvested RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 975 shares acquired under the ESPP Purchase on June 2, 2025."}],"balance_after":242346,"source":{"system":"sec-edgar","filing":"0001724311-25-000011","document":"wk-form4_1755218026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724311/000172431125000011/wk-form4_1755218026.xml","form_type":"4"}},{"id":1066482,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-08-15T00:33:05.000Z","date":"2025-08-13","kind":"sale","planned":true,"acquired":false,"shares":806,"price":14.64,"value":11799.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted December 11, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 128,405 Unvested RSUs."}],"balance_after":216585,"source":{"system":"sec-edgar","filing":"0001714899-25-000176","document":"wk-form4_1755217980.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000176/wk-form4_1755217980.xml","form_type":"4"}},{"id":1066481,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-08-15T00:33:05.000Z","date":"2025-08-12","kind":"sale","planned":true,"acquired":false,"shares":2937,"price":13.58,"value":39884.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $13.34 to $13.58 per share. Upon request by the Commission staff, the Issuer, or a\nsecurity holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 128,405 Unvested RSUs."}],"balance_after":217391,"source":{"system":"sec-edgar","filing":"0001714899-25-000176","document":"wk-form4_1755217980.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000176/wk-form4_1755217980.xml","form_type":"4"}},{"id":1072289,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-07T21:34:32.000Z","date":"2025-08-05","kind":"exercise","planned":false,"acquired":false,"shares":44655,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days."}],"balance_after":62500,"derivative":{"exercise_price":0.68,"expiration_date":"2025-08-20","underlying":"Common Stock","underlying_shares":44655},"source":{"system":"sec-edgar","filing":"0001714899-25-000153","document":"wk-form4_1754602468.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000153/wk-form4_1754602468.xml","form_type":"4"}},{"id":1072288,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-08-07T21:34:32.000Z","date":"2025-08-05","kind":"exercise","planned":false,"acquired":true,"shares":44655,"price":0.68,"value":30365.4,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 134,030 Unvested RSUs."}],"balance_after":220328,"source":{"system":"sec-edgar","filing":"0001714899-25-000153","document":"wk-form4_1754602468.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000153/wk-form4_1754602468.xml","form_type":"4"}},{"id":1088618,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":23347,"kind":"person","name":"Watts Ryan J.","position":1,"cik":"0001724310","reported_name":"Watts Ryan J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-07-11T21:13:23.000Z","date":"2025-07-09","kind":"exercise","planned":true,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option will vest on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter."}],"balance_after":20369,"derivative":{"exercise_price":5.28,"expiration_date":"2027-03-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001714899-25-000149","document":"wk-form4_1752268398.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1724310/000171489925000149/wk-form4_1752268398.xml","form_type":"4"}},{"id":1088617,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":23347,"kind":"person","name":"Watts Ryan J.","position":1,"cik":"0001724310","reported_name":"Watts Ryan J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-07-11T21:13:23.000Z","date":"2025-07-09","kind":"exercise","planned":true,"acquired":false,"shares":455282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days."}],"balance_after":622809,"derivative":{"exercise_price":0.68,"expiration_date":"2025-08-21","underlying":"Common Stock","underlying_shares":455282},"source":{"system":"sec-edgar","filing":"0001714899-25-000149","document":"wk-form4_1752268398.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1724310/000171489925000149/wk-form4_1752268398.xml","form_type":"4"}},{"id":1088616,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":23347,"kind":"person","name":"Watts Ryan J.","position":1,"cik":"0001724310","reported_name":"Watts Ryan J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-11T21:13:23.000Z","date":"2025-07-09","kind":"sale","planned":true,"acquired":false,"shares":495282,"price":15,"value":7429230.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported by the Reporting Person were made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 09/16/2024. The shares sold primarily relate to 455,282 stock options that expire on 08/21/2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $15.00 to $15.08 per share. Upon request by the Commission staff, the Issuer, or a\nsecurity holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 177,940 Unvested RSUs."}],"balance_after":253071,"source":{"system":"sec-edgar","filing":"0001714899-25-000149","document":"wk-form4_1752268398.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1724310/000171489925000149/wk-form4_1752268398.xml","form_type":"4"}},{"id":1088615,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":23347,"kind":"person","name":"Watts Ryan J.","position":1,"cik":"0001724310","reported_name":"Watts Ryan J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-11T21:13:23.000Z","date":"2025-07-09","kind":"exercise","planned":true,"acquired":true,"shares":40000,"price":5.28,"value":211200.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 177,940 Unvested RSUs."}],"balance_after":748353,"source":{"system":"sec-edgar","filing":"0001714899-25-000149","document":"wk-form4_1752268398.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724310/000171489925000149/wk-form4_1752268398.xml","form_type":"4"}},{"id":1088614,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":23347,"kind":"person","name":"Watts Ryan J.","position":1,"cik":"0001724310","reported_name":"Watts Ryan J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-11T21:13:23.000Z","date":"2025-07-09","kind":"exercise","planned":true,"acquired":true,"shares":455282,"price":0.68,"value":309591.76,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 177,940 Unvested RSUs."}],"balance_after":708353,"source":{"system":"sec-edgar","filing":"0001714899-25-000149","document":"wk-form4_1752268398.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724310/000171489925000149/wk-form4_1752268398.xml","form_type":"4"}},{"id":1121879,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non- Qualified Stock Option (right to buy)","published_at":"2025-06-05T21:02:52.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":31695,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F9","text":"31,695 Stock Options exercisable solely into Common Stock were granted under the Incentive Plan to Julian C. Baker in his capacity as a director of the Issuer. The Stock Options have a strike price of $13.93 and expire on June 3, 2035. One fourth of the Stock Options vest on June 3, 2026 with the remaining Stock Options vesting in 36 equal monthly installments beginning on July 3, 2026, subject to Julian C. Baker's continuous service on the Board through such vesting dates."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"31,695 Stock Options exercisable solely into Common Stock were granted under the Incentive Plan to Julian C. Baker in his capacity as a director of the Issuer. The Stock Options have a strike price of $13.93 and expire on June 3, 2035. One fourth of the Stock Options vest on June 3, 2026 with the remaining Stock Options vesting in 36 equal monthly installments beginning on July 3, 2026, subject to Julian C. Baker's continuous service on the Board through such vesting dates."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock (\"Stock Options\") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The acquisitions of the RSUs and Stock Options reported on this form represent a single grant to Julian C. Baker of 10,565 RSUs on Table I and 31,695 Stock Options on Table II. These grants, totaling 10,565 RSUs and 31,695 Stock Options for Julian C. Baker, are reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":31695,"derivative":{"exercise_price":13.93,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":31695},"source":{"system":"sec-edgar","filing":"0000950170-25-082472","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017025082472/ownership.xml","form_type":"4"}},{"id":1121878,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)uy)","published_at":"2025-06-05T21:02:52.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":31695,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F9","text":"31,695 Stock Options exercisable solely into Common Stock were granted under the Incentive Plan to Julian C. Baker in his capacity as a director of the Issuer. The Stock Options have a strike price of $13.93 and expire on June 3, 2035. One fourth of the Stock Options vest on June 3, 2026 with the remaining Stock Options vesting in 36 equal monthly installments beginning on July 3, 2026, subject to Julian C. Baker's continuous service on the Board through such vesting dates."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"31,695 Stock Options exercisable solely into Common Stock were granted under the Incentive Plan to Julian C. Baker in his capacity as a director of the Issuer. The Stock Options have a strike price of $13.93 and expire on June 3, 2035. One fourth of the Stock Options vest on June 3, 2026 with the remaining Stock Options vesting in 36 equal monthly installments beginning on July 3, 2026, subject to Julian C. Baker's continuous service on the Board through such vesting dates."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock (\"Stock Options\") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The acquisitions of the RSUs and Stock Options reported on this form represent a single grant to Julian C. Baker of 10,565 RSUs on Table I and 31,695 Stock Options on Table II. These grants, totaling 10,565 RSUs and 31,695 Stock Options for Julian C. Baker, are reported for each of the Funds as each has an indirect pecuniary interest in such securities."}],"balance_after":31695,"derivative":{"exercise_price":13.93,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":31695},"source":{"system":"sec-edgar","filing":"0000950170-25-082472","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017025082472/ownership.xml","form_type":"4"}},{"id":1121877,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T21:02:52.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":10565,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 10,565 restricted stock units (each, an \"RSU\") payable solely in common stock (\"Common Stock\") of Denali Therapeutics Inc. (the \"Issuer\") granted by the Issuer to Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") on June 3, 2025, pursuant to the Issuer's 2017 Equity Incentive Plan and Outside Director Compensation Policy (collectively \"Incentive Plan\"). The RSUs vest in four equal annual installments on June 3, 2026, June 3, 2027, June 3, 2028, and the earlier of June 3, 2029 or the day prior to the Issuer's Annual Meeting occurring after June 3, 2028, in each case subject to Julian C. Baker's continuous service on the board of directors of the Issuer (the \"Board\") through such vesting dates. Julian C. Baker serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock (\"Stock Options\") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The acquisitions of the RSUs and Stock Options reported on this form represent a single grant to Julian C. Baker of 10,565 RSUs on Table I and 31,695 Stock Options on Table II. These grants, totaling 10,565 RSUs and 31,695 Stock Options for Julian C. Baker, are reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":3415958,"source":{"system":"sec-edgar","filing":"0000950170-25-082472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017025082472/ownership.xml","form_type":"4"}},{"id":1121876,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T21:02:52.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":10565,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 10,565 restricted stock units (each, an \"RSU\") payable solely in common stock (\"Common Stock\") of Denali Therapeutics Inc. (the \"Issuer\") granted by the Issuer to Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") on June 3, 2025, pursuant to the Issuer's 2017 Equity Incentive Plan and Outside Director Compensation Policy (collectively \"Incentive Plan\"). The RSUs vest in four equal annual installments on June 3, 2026, June 3, 2027, June 3, 2028, and the earlier of June 3, 2029 or the day prior to the Issuer's Annual Meeting occurring after June 3, 2028, in each case subject to Julian C. Baker's continuous service on the board of directors of the Issuer (the \"Board\") through such vesting dates. Julian C. Baker serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock (\"Stock Options\") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The acquisitions of the RSUs and Stock Options reported on this form represent a single grant to Julian C. Baker of 10,565 RSUs on Table I and 31,695 Stock Options on Table II. These grants, totaling 10,565 RSUs and 31,695 Stock Options for Julian C. Baker, are reported for each of the Funds as each has an indirect pecuniary interest in such securities."}],"balance_after":336867,"source":{"system":"sec-edgar","filing":"0000950170-25-082472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017025082472/ownership.xml","form_type":"4"}},{"id":1121382,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-05T20:34:17.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":18111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":18111,"derivative":{"exercise_price":13.93,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":18111},"source":{"system":"sec-edgar","filing":"0001714899-25-000142","document":"wk-form4_1749155629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000142/wk-form4_1749155629.xml","form_type":"4"}},{"id":1121381,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T20:34:17.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":6037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,037 unvested RSUs."}],"balance_after":26075,"source":{"system":"sec-edgar","filing":"0001714899-25-000142","document":"wk-form4_1749155629.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000142/wk-form4_1749155629.xml","form_type":"4"}},{"id":1121380,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":35935,"kind":"person","name":"FLATLEY JAY T","position":1,"cik":"0001189130","reported_name":"FLATLEY JAY T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-05T20:33:18.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":18111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":18111,"derivative":{"exercise_price":13.93,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":18111},"source":{"system":"sec-edgar","filing":"0001714899-25-000141","document":"wk-form4_1749155513.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000141/wk-form4_1749155513.xml","form_type":"4"}},{"id":1121379,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":35935,"kind":"person","name":"FLATLEY JAY T","position":1,"cik":"0001189130","reported_name":"FLATLEY JAY T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T20:33:18.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":6037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,037 unvested RSUs."}],"balance_after":16220,"source":{"system":"sec-edgar","filing":"0001714899-25-000141","document":"wk-form4_1749155513.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000141/wk-form4_1749155513.xml","form_type":"4"}},{"id":1121378,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":12811,"kind":"person","name":"Klein Peter S","position":1,"cik":"0001478007","reported_name":"Klein Peter S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-05T20:31:24.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":18111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":18111,"derivative":{"exercise_price":13.93,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":18111},"source":{"system":"sec-edgar","filing":"0001714899-25-000140","document":"wk-form4_1749155428.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000140/wk-form4_1749155428.xml","form_type":"4"}},{"id":1121377,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":12811,"kind":"person","name":"Klein Peter S","position":1,"cik":"0001478007","reported_name":"Klein Peter S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T20:31:24.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":6037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,037 unvested RSUs."}],"balance_after":27533,"source":{"system":"sec-edgar","filing":"0001714899-25-000140","document":"wk-form4_1749155428.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000140/wk-form4_1749155428.xml","form_type":"4"}},{"id":1121376,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":32853,"kind":"person","name":"Krognes Steve E.","position":1,"cik":"0001666236","reported_name":"Krognes Steve E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-05T20:29:16.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":18111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":18111,"derivative":{"exercise_price":13.93,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":18111},"source":{"system":"sec-edgar","filing":"0001714899-25-000139","document":"wk-form4_1749155311.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000139/wk-form4_1749155311.xml","form_type":"4"}},{"id":1121375,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":32853,"kind":"person","name":"Krognes Steve E.","position":1,"cik":"0001666236","reported_name":"Krognes Steve E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T20:29:16.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":6037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,037 unvested RSUs."}],"balance_after":31794,"source":{"system":"sec-edgar","filing":"0001714899-25-000139","document":"wk-form4_1749155311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000139/wk-form4_1749155311.xml","form_type":"4"}},{"id":1121374,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-05T20:26:51.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":18111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":18111,"derivative":{"exercise_price":13.93,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":18111},"source":{"system":"sec-edgar","filing":"0001714899-25-000138","document":"wk-form4_1749155084.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000138/wk-form4_1749155084.xml","form_type":"4"}},{"id":1121373,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T20:26:51.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":6037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,037 unvested RSUs."}],"balance_after":15257,"source":{"system":"sec-edgar","filing":"0001714899-25-000138","document":"wk-form4_1749155084.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000138/wk-form4_1749155084.xml","form_type":"4"}},{"id":1121372,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":10183,"kind":"person","name":"Thornberry Nancy","position":1,"cik":"0001797826","reported_name":"Thornberry Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-05T20:25:53.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":18111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":18111,"derivative":{"exercise_price":13.93,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":18111},"source":{"system":"sec-edgar","filing":"0001714899-25-000137","document":"wk-form4_1749154899.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000137/wk-form4_1749154899.xml","form_type":"4"}},{"id":1121371,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":10183,"kind":"person","name":"Thornberry Nancy","position":1,"cik":"0001797826","reported_name":"Thornberry Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T20:25:53.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":6037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,037 unvested RSUs."}],"balance_after":24717,"source":{"system":"sec-edgar","filing":"0001714899-25-000137","document":"wk-form4_1749154899.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000137/wk-form4_1749154899.xml","form_type":"4"}},{"id":1121370,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-05T20:23:08.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":18111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":18111,"derivative":{"exercise_price":13.93,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":18111},"source":{"system":"sec-edgar","filing":"0001714899-25-000136","document":"wk-form4_1749154932.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000136/wk-form4_1749154932.xml","form_type":"4"}},{"id":1121369,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T20:23:08.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":6037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,037 unvested RSUs."}],"balance_after":1886576,"source":{"system":"sec-edgar","filing":"0001714899-25-000136","document":"wk-form4_1749154932.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000136/wk-form4_1749154932.xml","form_type":"4"}},{"id":1306724,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-09T01:26:37.000Z","date":"2025-01-07","kind":"sale","planned":false,"acquired":false,"shares":2907,"price":20.81,"value":60494.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 134,030 Unvested RSUs."}],"balance_after":175673,"source":{"system":"sec-edgar","filing":"0001714899-25-000051","document":"wk-form4_1736385991.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000051/wk-form4_1736385991.xml","form_type":"4"}},{"id":1306723,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-09T01:26:37.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":12255,"price":20.22,"value":247796.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.93 to $20.23 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 134,030 Unvested RSUs."}],"balance_after":178580,"source":{"system":"sec-edgar","filing":"0001714899-25-000051","document":"wk-form4_1736385991.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000051/wk-form4_1736385991.xml","form_type":"4"}},{"id":1306727,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":1736,"kind":"person","name":"Schuth Alexander O.","position":1,"cik":"0001724311","reported_name":"Schuth Alexander O.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COFO and Secretary"}}],"security":"Common Stock","published_at":"2025-01-09T01:25:44.000Z","date":"2025-01-07","kind":"sale","planned":false,"acquired":false,"shares":2907,"price":20.81,"value":60494.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 134,030 Unvested RSUs."}],"balance_after":244308,"source":{"system":"sec-edgar","filing":"0001714899-25-000050","document":"wk-form4_1736385937.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724311/000171489925000050/wk-form4_1736385937.xml","form_type":"4"}},{"id":1306726,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":1736,"kind":"person","name":"Schuth Alexander O.","position":1,"cik":"0001724311","reported_name":"Schuth Alexander O.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COFO and Secretary"}}],"security":"Common Stock","published_at":"2025-01-09T01:25:44.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":12255,"price":20.22,"value":247796.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.91 to $20.23 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 134,030 Unvested RSUs."}],"balance_after":247215,"source":{"system":"sec-edgar","filing":"0001714899-25-000050","document":"wk-form4_1736385937.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724311/000171489925000050/wk-form4_1736385937.xml","form_type":"4"}},{"id":1306729,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":23347,"kind":"person","name":"Watts Ryan J.","position":1,"cik":"0001724310","reported_name":"Watts Ryan J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-09T01:24:43.000Z","date":"2025-01-07","kind":"sale","planned":false,"acquired":false,"shares":7650,"price":20.81,"value":159196.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 177,940 Unvested RSUs."}],"balance_after":253071,"source":{"system":"sec-edgar","filing":"0001714899-25-000049","document":"wk-form4_1736385877.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724310/000171489925000049/wk-form4_1736385877.xml","form_type":"4"}},{"id":1306728,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":23347,"kind":"person","name":"Watts Ryan J.","position":1,"cik":"0001724310","reported_name":"Watts Ryan J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-09T01:24:43.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":29266,"price":20.22,"value":591758.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.91 to $20.23 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 177,940 Unvested RSUs."}],"balance_after":260721,"source":{"system":"sec-edgar","filing":"0001714899-25-000049","document":"wk-form4_1736385877.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724310/000171489925000049/wk-form4_1736385877.xml","form_type":"4"}},{"id":1306725,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":32853,"kind":"person","name":"Krognes Steve E.","position":1,"cik":"0001666236","reported_name":"Krognes Steve E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-09T01:23:57.000Z","date":"2025-01-07","kind":"sale","planned":false,"acquired":false,"shares":3339,"price":20.81,"value":69484.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,967 Unvested RSUs."}],"balance_after":25757,"source":{"system":"sec-edgar","filing":"0001714899-25-000048","document":"wk-form4_1736385830.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000048/wk-form4_1736385830.xml","form_type":"4"}},{"id":1308126,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":23347,"kind":"person","name":"Watts Ryan J.","position":1,"cik":"0001724310","reported_name":"Watts Ryan J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-07T23:59:45.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":162540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option shall vest on January 3, 2026, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date."}],"balance_after":162540,"derivative":{"exercise_price":21.26,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":162540},"source":{"system":"sec-edgar","filing":"0001714899-25-000028","document":"wk-form4_1736294379.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1724310/000171489925000028/wk-form4_1736294379.xml","form_type":"4"}},{"id":1308125,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":23347,"kind":"person","name":"Watts Ryan J.","position":1,"cik":"0001724310","reported_name":"Watts Ryan J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-07T23:59:45.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":54180,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2026 (the \"Vesting\nCommencement Date\") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service\nprovider of the Issuer through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 192,940 Unvested RSUs."}],"balance_after":289987,"source":{"system":"sec-edgar","filing":"0001714899-25-000028","document":"wk-form4_1736294379.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724310/000171489925000028/wk-form4_1736294379.xml","form_type":"4"}},{"id":1308124,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":1736,"kind":"person","name":"Schuth Alexander O.","position":1,"cik":"0001724311","reported_name":"Schuth Alexander O.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COFO and Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-07T23:57:55.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":162540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option shall vest on January 3, 2026, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date"}],"balance_after":162540,"derivative":{"exercise_price":21.26,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":162540},"source":{"system":"sec-edgar","filing":"0001714899-25-000027","document":"wk-form4_1736294268.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1724311/000171489925000027/wk-form4_1736294268.xml","form_type":"4"}},{"id":1308123,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":1736,"kind":"person","name":"Schuth Alexander O.","position":1,"cik":"0001724311","reported_name":"Schuth Alexander O.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COFO and Secretary"}}],"security":"Common Stock","published_at":"2025-01-07T23:57:55.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":54180,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2026 (the \"Vesting\nCommencement Date\") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service\nprovider of the Issuer through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 141,530 Unvested RSUs."}],"balance_after":259470,"source":{"system":"sec-edgar","filing":"0001714899-25-000027","document":"wk-form4_1736294268.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724311/000171489925000027/wk-form4_1736294268.xml","form_type":"4"}},{"id":1308119,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-07T23:56:19.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":162540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the option shall vest on January 3, 2026, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date."}],"balance_after":162540,"derivative":{"exercise_price":21.26,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":162540},"source":{"system":"sec-edgar","filing":"0001714899-25-000026","document":"wk-form4_1736294172.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000026/wk-form4_1736294172.xml","form_type":"4"}},{"id":1308118,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-07T23:56:19.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":54180,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2026 (the \"Vesting Commencement Date\") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 141,530  Unvested RSUs."}],"balance_after":190835,"source":{"system":"sec-edgar","filing":"0001714899-25-000026","document":"wk-form4_1736294172.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000026/wk-form4_1736294172.xml","form_type":"4"}},{"id":1314898,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":32853,"kind":"person","name":"Krognes Steve E.","position":1,"cik":"0001666236","reported_name":"Krognes Steve E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-03T21:14:23.000Z","date":"2024-12-31","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":20.25,"value":607500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted December 1, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $20.10 to $20.55 per share. Upon request by the Commission staff, the Issuer, or a\nsecurity holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects an allocation of 30,000 shares from the Steven Edward Krognes Revocable Trust to the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 13,467 Unvested RSUs."}],"balance_after":29096,"source":{"system":"sec-edgar","filing":"0001714899-25-000002","document":"wk-form4_1735938858.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000002/wk-form4_1735938858.xml","form_type":"4"}},{"id":1314897,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-03T21:13:51.000Z","date":"2025-01-02","kind":"sale","planned":true,"acquired":false,"shares":3080,"price":20.91,"value":64402.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $20.75 to $21.06 per share. Upon request by the Commission staff, the Issuer, or a security holder of  the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,967 unvested RSUs."}],"balance_after":107976,"source":{"system":"sec-edgar","filing":"0001714899-25-000001","document":"wk-form4_1735938823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000001/wk-form4_1735938823.xml","form_type":"4"}},{"id":1319845,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":1736,"kind":"person","name":"Schuth Alexander O.","position":1,"cik":"0001724311","reported_name":"Schuth Alexander O.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COFO and Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2024-12-31T21:18:12.000Z","date":"2024-12-27","kind":"exercise","planned":false,"acquired":false,"shares":6708,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter."}],"balance_after":46671,"derivative":{"exercise_price":5.28,"expiration_date":"2027-03-07","underlying":"Common Stock","underlying_shares":6708},"source":{"system":"sec-edgar","filing":"0001714899-24-000236","document":"wk-form4_1735679885.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1724311/000171489924000236/wk-form4_1735679885.xml","form_type":"4"}},{"id":1319844,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":1736,"kind":"person","name":"Schuth Alexander O.","position":1,"cik":"0001724311","reported_name":"Schuth Alexander O.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COFO and Secretary"}}],"security":"Common Stock","published_at":"2024-12-31T21:18:12.000Z","date":"2024-12-27","kind":"exercise","planned":false,"acquired":true,"shares":6708,"price":5.28,"value":35418.24,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 118,810 Unvested RSUs."}],"balance_after":205290,"source":{"system":"sec-edgar","filing":"0001714899-24-000236","document":"wk-form4_1735679885.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724311/000171489924000236/wk-form4_1735679885.xml","form_type":"4"}},{"id":1349450,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-27T21:44:42.000Z","date":"2024-11-25","kind":"exercise","planned":false,"acquired":false,"shares":17845,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the\nshares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days."}],"balance_after":107155,"derivative":{"exercise_price":0.68,"expiration_date":"2025-08-20","underlying":"Common Stock","underlying_shares":17845},"source":{"system":"sec-edgar","filing":"0001714899-24-000235","document":"wk-form4_1732743876.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000235/wk-form4_1732743876.xml","form_type":"4"}},{"id":1349449,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-11-27T21:44:42.000Z","date":"2024-11-25","kind":"exercise","planned":false,"acquired":true,"shares":17845,"price":0.68,"value":12134.6,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 118,810 Unvested RSUs."}],"balance_after":136655,"source":{"system":"sec-edgar","filing":"0001714899-24-000235","document":"wk-form4_1732743876.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000235/wk-form4_1732743876.xml","form_type":"4"}},{"id":1351019,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":1736,"kind":"person","name":"Schuth Alexander O.","position":1,"cik":"0001724311","reported_name":"Schuth Alexander O.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COFO and Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-26T22:19:27.000Z","date":"2024-11-22","kind":"exercise","planned":false,"acquired":false,"shares":20516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days."}],"balance_after":124562,"derivative":{"exercise_price":0.68,"expiration_date":"2025-08-20","underlying":"Common Stock","underlying_shares":20516},"source":{"system":"sec-edgar","filing":"0001714899-24-000234","document":"wk-form4_1732659560.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1724311/000171489924000234/wk-form4_1732659560.xml","form_type":"4"}},{"id":1351018,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":1736,"kind":"person","name":"Schuth Alexander O.","position":1,"cik":"0001724311","reported_name":"Schuth Alexander O.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COFO and Secretary"}}],"security":"Common Stock","published_at":"2024-11-26T22:19:27.000Z","date":"2024-11-22","kind":"exercise","planned":false,"acquired":true,"shares":20516,"price":0.68,"value":13950.88,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Includes 118,810 Unvested RSUs."}],"balance_after":198582,"source":{"system":"sec-edgar","filing":"0001714899-24-000234","document":"wk-form4_1732659560.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724311/000171489924000234/wk-form4_1732659560.xml","form_type":"4"}},{"id":1366626,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-11-13T21:18:59.000Z","date":"2024-11-11","kind":"exercise","planned":true,"acquired":false,"shares":47165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the option shall vest on December 7, 2018 and an additional 1/48 of the shares vest monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2027-12-06","underlying":"Common Stock","underlying_shares":47165},"source":{"system":"sec-edgar","filing":"0001714899-24-000219","document":"wk-form4_1731532732.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000219/wk-form4_1731532732.xml","form_type":"4"}},{"id":1366625,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-13T21:18:59.000Z","date":"2024-11-11","kind":"sale","planned":true,"acquired":false,"shares":32312,"price":32.87,"value":1062095.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted August 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $32.54 to $33.28 per share. Upon request by the Commission staff, the Issuer, or a\nsecurity holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 5,967 Unvested RSUs."}],"balance_after":9220,"source":{"system":"sec-edgar","filing":"0001714899-24-000219","document":"wk-form4_1731532732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000219/wk-form4_1731532732.xml","form_type":"4"}},{"id":1366624,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-13T21:18:59.000Z","date":"2024-11-11","kind":"sale","planned":true,"acquired":false,"shares":27129,"price":32.09,"value":870569.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted August 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $31.54 to $32.53 per share. Upon request by the Commission staff, the Issuer, or a\nsecurity holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 5,967 Unvested RSUs."}],"balance_after":41532,"source":{"system":"sec-edgar","filing":"0001714899-24-000219","document":"wk-form4_1731532732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000219/wk-form4_1731532732.xml","form_type":"4"}},{"id":1366623,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-13T21:18:59.000Z","date":"2024-11-11","kind":"exercise","planned":true,"acquired":true,"shares":47165,"price":18,"value":848970.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 5,967 Unvested RSUs."}],"balance_after":68661,"source":{"system":"sec-edgar","filing":"0001714899-24-000219","document":"wk-form4_1731532732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000219/wk-form4_1731532732.xml","form_type":"4"}},{"id":1369045,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":1736,"kind":"person","name":"Schuth Alexander O.","position":1,"cik":"0001724311","reported_name":"Schuth Alexander O.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COFO and Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-12T21:44:51.000Z","date":"2024-11-07","kind":"exercise","planned":true,"acquired":false,"shares":15558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter."}],"balance_after":53379,"derivative":{"exercise_price":5.28,"expiration_date":"2027-03-07","underlying":"Common Stock","underlying_shares":15558},"source":{"system":"sec-edgar","filing":"0001714899-24-000218","document":"wk-form4_1731447884.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1724311/000171489924000218/wk-form4_1731447884.xml","form_type":"4"}},{"id":1369044,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":1736,"kind":"person","name":"Schuth Alexander O.","position":1,"cik":"0001724311","reported_name":"Schuth Alexander O.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COFO and Secretary"}}],"security":"Common Stock","published_at":"2024-11-12T21:44:51.000Z","date":"2024-11-07","kind":"sale","planned":true,"acquired":false,"shares":300,"price":31.29,"value":9387.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $31.27 to $31.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 118,810 Unvested RSUs."}],"balance_after":178066,"source":{"system":"sec-edgar","filing":"0001714899-24-000218","document":"wk-form4_1731447884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1724311/000171489924000218/wk-form4_1731447884.xml","form_type":"4"}},{"id":1369043,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":1736,"kind":"person","name":"Schuth Alexander O.","position":1,"cik":"0001724311","reported_name":"Schuth Alexander O.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COFO and Secretary"}}],"security":"Common Stock","published_at":"2024-11-12T21:44:51.000Z","date":"2024-11-07","kind":"sale","planned":true,"acquired":false,"shares":2925,"price":30.72,"value":89856.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.21 to $31.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 118,810 Unvested RSUs."}],"balance_after":178366,"source":{"system":"sec-edgar","filing":"0001714899-24-000218","document":"wk-form4_1731447884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1724311/000171489924000218/wk-form4_1731447884.xml","form_type":"4"}},{"id":1369042,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":1736,"kind":"person","name":"Schuth Alexander O.","position":1,"cik":"0001724311","reported_name":"Schuth Alexander O.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COFO and Secretary"}}],"security":"Common Stock","published_at":"2024-11-12T21:44:51.000Z","date":"2024-11-07","kind":"sale","planned":true,"acquired":false,"shares":12333,"price":29.68,"value":366043.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.21 to $30.20 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 118,810 Unvested RSUs."}],"balance_after":181291,"source":{"system":"sec-edgar","filing":"0001714899-24-000218","document":"wk-form4_1731447884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724311/000171489924000218/wk-form4_1731447884.xml","form_type":"4"}},{"id":1369041,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":1736,"kind":"person","name":"Schuth Alexander O.","position":1,"cik":"0001724311","reported_name":"Schuth Alexander O.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COFO and Secretary"}}],"security":"Common Stock","published_at":"2024-11-12T21:44:51.000Z","date":"2024-11-07","kind":"exercise","planned":true,"acquired":true,"shares":15558,"price":5.28,"value":82146.24,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 118,810 Unvested RSUs."}],"balance_after":193624,"source":{"system":"sec-edgar","filing":"0001714899-24-000218","document":"wk-form4_1731447884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724311/000171489924000218/wk-form4_1731447884.xml","form_type":"4"}},{"id":1369019,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-12T21:43:29.000Z","date":"2024-11-07","kind":"sale","planned":true,"acquired":false,"shares":1020,"price":30,"value":30600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 21, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,967 unvested RSUs."}],"balance_after":111056,"source":{"system":"sec-edgar","filing":"0001714899-24-000217","document":"wk-form4_1731447801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000217/wk-form4_1731447801.xml","form_type":"4"}},{"id":1375529,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T21:21:27.000Z","date":"2024-11-01","kind":"sale","planned":true,"acquired":false,"shares":3080,"price":27.07,"value":83375.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $26.60 to $27.41 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,967 unvested RSUs."}],"balance_after":112076,"source":{"system":"sec-edgar","filing":"0001714899-24-000208","document":"wk-form4_1730841680.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000208/wk-form4_1730841680.xml","form_type":"4"}},{"id":1382981,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":23347,"kind":"person","name":"Watts Ryan J.","position":1,"cik":"0001724310","reported_name":"Watts Ryan J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-10-22T20:30:57.000Z","date":"2024-10-18","kind":"exercise","planned":true,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days."}],"balance_after":1078091,"derivative":{"exercise_price":0.68,"expiration_date":"2025-08-20","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001714899-24-000206","document":"wk-form4_1729629050.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1724310/000171489924000206/wk-form4_1729629050.xml","form_type":"4"}},{"id":1382980,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":23347,"kind":"person","name":"Watts Ryan J.","position":1,"cik":"0001724310","reported_name":"Watts Ryan J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-10-22T20:30:57.000Z","date":"2024-10-18","kind":"sale","planned":true,"acquired":false,"shares":40000,"price":27.69,"value":1107600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $27.49 to $28.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 197,200 Unvested RSUs."}],"balance_after":235807,"source":{"system":"sec-edgar","filing":"0001714899-24-000206","document":"wk-form4_1729629050.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724310/000171489924000206/wk-form4_1729629050.xml","form_type":"4"}},{"id":1382979,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":23347,"kind":"person","name":"Watts Ryan J.","position":1,"cik":"0001724310","reported_name":"Watts Ryan J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-10-22T20:30:57.000Z","date":"2024-10-18","kind":"exercise","planned":true,"acquired":true,"shares":40000,"price":0.68,"value":27200.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 197,200 Unvested RSUs."}],"balance_after":275807,"source":{"system":"sec-edgar","filing":"0001714899-24-000206","document":"wk-form4_1729629050.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724310/000171489924000206/wk-form4_1729629050.xml","form_type":"4"}},{"id":1394520,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":32853,"kind":"person","name":"Krognes Steve E.","position":1,"cik":"0001666236","reported_name":"Krognes Steve E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-02T20:37:42.000Z","date":"2024-09-30","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":29.03,"value":870900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted December 1, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.50 to $29.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects an allocation of 26,419 shares from the Steven Edward Krognes Revocable Trust to the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 13,467 Unvested RSUs."}],"balance_after":29096,"source":{"system":"sec-edgar","filing":"0001714899-24-000200","document":"wk-form4_1727901447.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000200/wk-form4_1727901447.xml","form_type":"4"}},{"id":1406659,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-16T20:17:52.000Z","date":"2024-09-13","kind":"sale","planned":true,"acquired":false,"shares":1020,"price":30,"value":30600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 21, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,967 unvested RSUs."}],"balance_after":115156,"source":{"system":"sec-edgar","filing":"0001714899-24-000199","document":"wk-form4_1726517865.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000199/wk-form4_1726517865.xml","form_type":"4"}}],"next_cursor":"2024-09-16T20:17:52.000000Z,1406659"}